Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05308056
Other study ID # 276915
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 19, 2022
Est. completion date February 6, 2023

Study information

Verified date February 2022
Source Region Örebro County
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Aim: To describe anesthetic depth using spectal edge frequency (SEF) and density spectral array (DSA) and its relation to treatment effect of electroconvulsive therapy (ECT). Study design: Observational study Primary outcomes: SEF, DSA and treatment effect of ECT. Method: SEF and DSA si measured using a commercially available monitor for depth of anesthesia. Treatment effect of ECT will be evaluated using hemodynamic, electroencephalographic and clinical variables.


Description:

Background Electroconvulsive therapy (ECT) is an effective therapy for severe depression where an electric current is applied to the brain to induce an epileptic seizure (1). The success of ECT is dependent upon the degree and quality of epileptic activity (2). ECT is normally administered after administering a muscle relaxant to prevent the seizure activity from causing muculoskeletal injuries. To tolerate the muscle relaxant the entire procedure is performed under general anesthesia. Most hypnotics have anti-convulsant effects and therefore counteract the effects of ECT (3). This implies that deep anesthesia hinders an optimal treatment effect of ECT which is supported by observational data (4). This relation has been proven with lighter anesthesia measured through bispectral index (BIS) correlating to longer seizure duration (5). BIS is not optimized to estimate the depth of anesthesia under very dynamic anesthetic protocols as there is an inherent latency in the computation of the BIS value. Anesthesia for ECT generally consists only of induction and recovery with no stable anesthetic phase making BIS an inappropriate measure of anesthetic depth. Indices of anesthetic depth that are derived directly from the processed EEG-signal have a negligent latency and can therefore be used with more precision during anesthesia for ECT. Spectral edge frequency (SEF) is the frequency under which 95 % of the total amplitude of the EEG-signal is found and it decreases with increasing depths of anesthesia. The density spectral array (DSA) is a graphic representation of the frequency and amplitude of the EEG signal over time and it is possible to interpret the DSA in real time without extensive training. The SEF and DSA have not, to our knowledge, been previously tested during general anesthesia for ECT. In the postictal phase during recovery from ECT some patients become agitated and confused (6). This condition is not clearly defined in the literature but is commonly referred to as postictal agitation (PIA) and due to differing definitions the incidence is difficult to estimate. Incidences in the range of 10-20 % have been reported (7). In the post-operative period after cardiac surgery decreased regional cerebral oxygen saturation (SrcO2) has been linked to post-operative confusion (8). A possible link between decreased SrcO2 and PIA has not been studied before. Aim The aim of this research project is two-fold: 1. To study the relation between anesthetic depth measured with SEF and DSA and the quality of epileptic activity during ECT. 2. To study the relation between SrcO2 and PIA during ECT. Hypotheses 1. Lighter depths of anesthesia as measured by SEF and DSA have a positive correlation with epileptic seizure quality during ECT. 2. SrcO2 during ECT has an inverse correlation with the incidence of PIA. Method Setting and recruitment The study will be performed at the ECT-unit of the university hospital in Örebro. General anesthesia is provided by a nurse specially trained in anesthesia and an anesthesiologist. ECT is provided by specially trained nurses and staff at the ECT-unit. Patients recover from the postictal phase in an adjacent recovery room. Patients undergoing ECT through the outpatient clinic will be recruited to the study. Anesthetic protocol The protocol for anesthesia and ECT will be the same as is being used clinically at the ECT-unit. After preoxygenation anesthesia is induced using thiopental. After confirmation of adequate anesthetic depth (failure to respond to verbal command) suxamethonium is administered. Doses are chosen by the anesthesiologist. Patients are admitted to the recovery room when breathing spontaneously and can maintain a patent airway. Data collection SEF and DSA will be measured continuously from before pre-oxygenation to admittance to the recovery room using a SedLine® (Masimo, Irvine, CA, USA) monitor. The monitor will be blinded during the procedure so as not to affect the staff in any way. SrcO2 will be measured using the same monitor during the same period. Data regarding the seizure duration will be gathered from the electronic patient records. The staff caring for the postictal patients will estimate the degree of PIA according to previously used numerical scale (9).Data will be presented as mean ± SD or median (IQR) according to their distribution. Statistical analysis will be performed using a logistic regression model adjusted for potential confounders such as type of psychiatric medication, age, bilateral or unilateral stimulation.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date February 6, 2023
Est. primary completion date February 6, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Admitted for a course of ECT Exclusion Criteria: - Not able to attach electrodes for measurement of depth of anesthesia due to eg. skin condition.

Study Design


Intervention

Device:
Depth of anesthesia monitor, SedLine® (Masimo, Irvine, CA, USA)
The device monitors the patient's electroencephalogram using electrodes applied to the forehead.

Locations

Country Name City State
Sweden Universitetssjukhuset Örebro Örebro Bok 1613

Sponsors (1)

Lead Sponsor Collaborator
Region Örebro County

Country where clinical trial is conducted

Sweden, 

References & Publications (8)

Eertmans W, De Deyne C, Genbrugge C, Marcus B, Bouneb S, Beran M, Fret T, Gutermann H, Boer W, Vander Laenen M, Heylen R, Mesotten D, Vanelderen P, Jans F. Association between postoperative delirium and postoperative cerebral oxygen desaturation in older patients after cardiac surgery. Br J Anaesth. 2020 Feb;124(2):146-153. doi: 10.1016/j.bja.2019.09.042. Epub 2019 Dec 18. — View Citation

Guerrier G, Gianni MA. The effectiveness of BIS monitoring during electro-convulsive therapy: A systematic review and meta-analysis. J Clin Anesth. 2019 Dec;58:100-104. doi: 10.1016/j.jclinane.2019.05.006. Epub 2019 May 28. — View Citation

Kronsell A, Nordenskjold A, Bell M, Amin R, Mittendorfer-Rutz E, Tiger M. The effect of anaesthetic dose on response and remission in electroconvulsive therapy for major depressive disorder: nationwide register-based cohort study. BJPsych Open. 2021 Mar 23;7(2):e71. doi: 10.1192/bjo.2021.31. — View Citation

Li X, Cheng N, Deng Y, Du J, Zhang M, Guo Y, Hei Z. Incidence and risk factors for postictal delirium in patients after electroconvulsive therapy in China. Asian J Psychiatr. 2020 Oct;53:102361. doi: 10.1016/j.ajp.2020.102361. Epub 2020 Aug 25. No abstract available. — View Citation

Minelli A, Abate M, Zampieri E, Gainelli G, Trabucchi L, Segala M, Sartori R, Gennarelli M, Conca A, Bortolomasi M. Seizure Adequacy Markers and the Prediction of Electroconvulsive Therapy Response. J ECT. 2016 Jun;32(2):88-92. doi: 10.1097/YCT.0000000000000274. — View Citation

Tsujii T, Uchida T, Suzuki T, Mimura M, Hirano J, Uchida H. Factors Associated With Delirium Following Electroconvulsive Therapy: A Systematic Review. J ECT. 2019 Dec;35(4):279-287. doi: 10.1097/YCT.0000000000000606. — View Citation

UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003 Mar 8;361(9360):799-808. doi: 10.1016/S0140-6736(03)12705-5. — View Citation

Zolezzi M. Medication management during electroconvulsant therapy. Neuropsychiatr Dis Treat. 2016 Apr 19;12:931-9. doi: 10.2147/NDT.S100908. eCollection 2016. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in spectral edge frequency The spectral edge frequency of the patients electroencephalogram Monitored before, during and after ECT. Total monitoring time is apporximately 30 minutes per patient.
Primary Change in density spectral array The density spectral array of the patients electroencephalogram Monitored before, during and after ECT. Total monitoring time is approximately 30 minutes per patient.
Primary Duration of convulsive activity Measures the duration of both motor and encephalographic convulsions directly following ECT. Monitored immediately after administration of ECT.
Primary Postictal supression Measures the degree of encephalographic supression directly following ECT Monitored immediately after administration of ECT.
Primary Need for restimulation Measures if there is a need for restimulation directly after evaluating the effect of an administered ECT. Monitored immediately after administration of ECT.
Primary Change in heart rate. Mesaures the increase in heart rate directly following ECT. Monitored immediately after administration of ECT.
Secondary Awareness Patients will be asked if they can recall any part of the tratment from induction of anesthesia until administration of ECT. Patients are asked at a follow up visit approximately 1 week after a course of several ECT:s.
Secondary Adverse effects of ECT Occurence of adverse effects following ECT, evaluated using the CRPS-memory questionnaire. Patients are asked at a follow up visit approximately 1 week after a course of several ECT:s.
Secondary Desaturation Occurence of saturation <92 % at any point during anesthesia and ECT. Monitored immediately before pre-oxygenation, during the entire ECT and until the patient has recovered. Approximately 1 hours of total monitoring time.
Secondary End-tidal CO2 Measurement of end-tidal CO2 During induction of general anesthesia
Secondary Change in depressive symtoms Effect of ECT on patients' symptoms and quality of life. Evaluated using the self-asessed Montgomery Åsberg Depression Rating Scale (MADRS-S), 0-57 points. A higher score indicate more severe disease. Patients are asked at a follow up visit approximately 1 week after a course of several ECT:s and before ECT.
Secondary Clinical assessment of depth of anesthesia The treating anesthesiologist will be asked to asses the depth of anesthesia. The anesthesiologist is asked after induction of general anesthesia. The terms too heavily sedated, too lightly sedated and adequate level of sedation is used. Monitored immediately before pre-oxygenation, during the entire ECT and until the patient leaves the recovery ward. Approximately 1 hour of total monitoring time.
Secondary Regional cerebral oxygen saturation Measured using near-infrared spectroscopy Before, during and after anesthesia and ECT
Secondary Occurence of post-ictal agitation Registered in the recovery ward following ECT. A scale using three levels of agitation is used by the recovery staff. Higher scores indicate increasing levels of agitation. Monitored in the recovery suite
Secondary Change in quality of life Effect of ECT on patients' symptoms and quality of life. Evaluated using EruroQol 5-Dimensions score (EQ-5D), each quiestion is scored 1-3 or 1-5 points. A higher score indicates worse health related problems. Patients are asked at a follow up visit approximately 1 week after a course of several ECT:s and before ECT.
Secondary Change in illness severity Effect of ECT on patients' symptoms and quality of life. Evaluated using Clinial global impressions scale (CGI), each question is scored 1-7 points. A higher score indicates higher illness severity. Patients are asked at a follow up visit approximately 1 week after a course of several ECT:s and before ECT.
See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Terminated NCT03230097 - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year Phase 2
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT02874573 - Tocilizumab in Schizophrenia Phase 1
Terminated NCT02584114 - Brain Effects of Memory Training in Early Psychosis N/A
Completed NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Terminated NCT02841956 - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement N/A
Completed NCT01981356 - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis Phase 0
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Recruiting NCT02848469 - Irish Omega-3 Study Phase 2
Recruiting NCT02009969 - Serial Comparisons of Abdominal and Neurological MRI Scans N/A
Completed NCT02648321 - Motivational Intervention for Physical Activity in Psychosis N/A
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00130923 - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Phase 4
Completed NCT00455234 - Rapid Tranquillization Trial: TREC-India II Phase 3
Completed NCT00844922 - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) Phase 2
Completed NCT00130676 - A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression Phase 3